Akt1-IN-8 (Compound JL18) is a potent AKT1 kinase inhibitor with oral bioavailability of 41% and an IC50 value of 8.8 nM. It exhibits significant antiproliferative effects against PC-3 prostate cancer cells, with an IC50 of 3.0 µM. Akt1-IN-8 also reduces phosphorylated GSK3beta levels.
Molekulargewicht:
551.278
CAS Nummer:
[2247688-87-3]
Formel:
C21H25Br2N7O
Target-Kategorie:
Akt
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten